Drugs in Dev. Hepatology (Liver, Pancreatic, Gall Bladder)
Phase IV
Lead Product(s) : Saroglitazar magnesium
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Starts Trial to Generate Data on Effect of Saroglitazar Mg in NAFLD Patients
Details : Lipaglyn (saroglitazar magnesium) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of non-alcoholic fatty liver disease (NAFLD) patients with comorbidities and hypertriglyceridaemia in Type 2 diabetes (T2D).
Product Name : Lipaglyn
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2023
Lead Product(s) : Saroglitazar magnesium
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Obeticholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Intercept Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC
Details : COBALT study in advanced PBC, previously terminated early due to feasibility challenges, did not demonstrate a statistically significant difference in clinical endpoints between Ocaliva (obeticholic acid) and placebo.
Product Name : Ocaliva
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2022
Lead Product(s) : Obeticholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
